Overview

BPC-157 is a 15-amino-acid fragment characterized in gastric peptide research. The cited publications investigate experimental tissue and gastrointestinal models. Those findings do not establish a human treatment use.

Molecular structure

The reported amino-acid sequence is GEPPPGKPADDAGLV. This is a pentadecapeptide: a chain of 15 amino-acid residues. Molecular identity and purity require analytical verification for any research sample.

Mechanism under investigation

Published rat and cell studies examine tissue responses and tendocyte growth. The cited work does not establish a single confirmed human molecular target or a clinically validated mechanism.

Research contexts

The cited studies include rat Achilles tendon injury, rat ligament injury, and rat gastric-lesion models. These are experimental research contexts rather than recommended human applications.

Evidence limits

The cited tendon, ligament, and gastric studies are preclinical. Animal and in-vitro results cannot be directly converted into claims about human efficacy, safety, or use.

Primary sources

• Rat Achilles tendon and tendocyte study (PMID 14554208)
• Rat ligament study (PMID 20225319)
• Rat gastric-lesion study (PMID 7904712)

Overview

Semaglutide is a GLP-1 analog whose molecular design combines receptor activity with albumin-binding chemistry. This record focuses on structure and research context, not individual treatment decisions.

Molecular structure

The discovery study describes a GLP-1 peptide analog with a fatty-acid moiety and linker. That chemical modification contributes to albumin affinity while preserving GLP-1 receptor activity.

Mechanism under investigation

A cryo-electron-microscopy study reports a semaglutide-bound GLP-1 receptor–Gs complex. Receptor activation and albumin association are separate properties examined in molecular research.

Research contexts

Investigators study GLP-1 receptor signaling, peptide engineering, albumin association, and metabolic clinical endpoints. Molecular papers answer structure and design questions; clinical questions require direct trial evidence.

Evidence limits

A receptor structure or in-vitro potency measure does not establish an outcome for an individual. Clinical conclusions depend on the specific population, formulation, endpoint, and regulatory label.

Primary sources

• Semaglutide discovery and peptide design (PMID 26308095)
• Semaglutide-bound GLP-1R structure (PMID 34260945)
• STEP 1 randomized trial (PMID 33567185)

Overview

Tirzepatide is a 39-amino-acid peptide studied for activity at both the GIP and GLP-1 receptors. Its research record separates receptor-level observations from clinical endpoints.

Molecular structure

Structural work describes a linear 39-residue peptide. Its sequence contains GIP-related residues that contribute to receptor interactions investigated in cryo-electron-microscopy studies.

Mechanism under investigation

Original receptor-structure studies report tirzepatide bound to GIPR and GLP-1R complexes. These findings explain molecular dual agonism; they do not by themselves establish any individual clinical outcome.

Research contexts

Researchers investigate incretin-receptor binding, downstream signaling, and metabolic clinical endpoints. Study populations and endpoints must be checked directly before comparing clinical findings.

Evidence limits

Receptor behavior, preclinical measures, and clinical outcomes are different evidence layers. Do not infer treatment suitability, safety, or expected results from structural data alone.

Primary sources

• Dual incretin receptor structural study (PMID 35333651)
• GIPR and GLP-1R cryo-EM study (PMID 35217653)
• SURMOUNT-1 randomized trial (PMID 35658024)

Overview

5-Amino-1MQ is 5-amino-1-methylquinolinium, a small molecule rather than an amino-acid peptide. Researchers have studied it as an inhibitor of nicotinamide N-methyltransferase (NNMT) in biochemical assays, adipocytes, and high-fat-diet mouse models.

Molecular structure

PubChem records the 5-amino-1-methylquinolinium cation as C10H11N2+. It is an aromatic quinolinium structure with no peptide chain. The chemical form and identity of a Method lot require analytical confirmation.

Mechanism under investigation

An original study measured NNMT inhibition and changes in 1-methylnicotinamide and related metabolites in differentiated adipocytes. These are laboratory measurements, not a validated human metabolic mechanism.

Research contexts

Published work includes cell assays and high-fat-diet mouse studies measuring adipose and metabolic variables. The cited work does not establish a human clinical use.

Evidence limits

The principal source studies are preclinical. Mouse body-composition findings and cell metabolite measurements cannot establish human efficacy or safety. Pep-pedia's peptide classification is not used.

Primary sources

• PubChem small-molecule identity (CID 950107)
• NNMT cell and mouse study (PMID 29155147)
• Mouse metabolic study (PMID 39161060)

Overview

AHK-Cu is a copper complex of the alanine-histidine-lysine tripeptide. A published experiment examined human hair follicles outside the body and cultured dermal papilla cells. It does not establish a clinical hair-growth effect.

Molecular structure

The peptide has three residues: alanine, histidine, and lysine. PubChem lists an AHK-Cu copper-complex form; actual lot composition and salt form need independent confirmation.

Mechanism under investigation

The original study measured follicle elongation ex vivo and dermal papilla cell proliferation in culture. It also explored apoptosis-related markers. These experiments do not prove a mechanism in living humans.

Research contexts

Research contexts include isolated human hair follicles and cultured dermal papilla cells. These are laboratory models rather than patient outcomes.

Evidence limits

The cited evidence is ex vivo and in vitro. It cannot support a clinical efficacy claim. Formulation studies cited by Pep-pedia are not substitutes for compound-specific outcome studies.

Primary sources

• Human follicle and papilla-cell study (PMID 17703734)
• PubChem AHK-Cu form (CID 168431292)

Overview

AOD9604 is a synthetic hexadecapeptide based on the carboxyl-terminal region of human growth hormone, with an added N-terminal tyrosine. A published analysis summarizes six controlled human trials focused on safety and tolerability.

Molecular structure

The published clinical material is described as Tyr-hGH(177–191), sequence YLRIVQCRSVEGSCGF. That published sequence does not establish the identity or purity of a Method lot.

Mechanism under investigation

Animal and cellular work explored lipid-metabolism responses. The cited human analysis evaluated safety measures including IGF-1 and glucose handling; it does not establish a clinically validated human efficacy mechanism.

Research contexts

Original research includes rodent metabolic models and six controlled human studies, most involving adults meeting defined metabolic-study eligibility criteria. The human publication chiefly analyzes safety and tolerability.

Evidence limits

The human safety analysis should not be converted into a claim of human efficacy. Study formulations, routes, and populations vary, and the findings do not establish equivalence to Method inventory.

Primary sources

• Human safety analysis, six trials (DOI 10.4021/jem157w)
• Original obese-rat fragment study (PMID 11146367)

Overview

Cagrilintide is a stable, lipidated amylin analogue developed for clinical research. A randomized phase 2 trial studied cagrilintide alone in adults meeting specified weight-related eligibility criteria. Combination trials with semaglutide must be identified as combination evidence.

Molecular structure

The molecule is a modified amylin peptide with lipidation intended to extend activity. Exact sequence and material identity for a Method lot require independent confirmation.

Mechanism under investigation

The compound was engineered as a long-acting amylin analogue. The cited phase 2 study measured body-weight and safety endpoints; it does not establish all downstream pathways or equivalence to catalog material.

Research contexts

Published research includes a cagrilintide-alone randomized phase 2 trial and later studies involving coadministration with semaglutide. The latter cannot be credited to cagrilintide alone.

Evidence limits

The monotherapy and combination findings must remain separate. Trial results apply to tested formulations and enrolled populations. Pep-pedia's highlighted REDEFINE 1 combination outcome is not presented as a cagrilintide-alone effect.

Primary sources

• Cagrilintide development study (PMID 34288673)
• Cagrilintide-alone phase 2 trial (PMID 34798060)
• REDEFINE 1 combination trial (DOI 10.1056/NEJMoa2502081)

Overview

Cerebrolysin is a complex preparation of low-molecular-weight peptides and amino acids derived from porcine brain. It has no single amino-acid sequence. Clinical studies have investigated outcomes after traumatic brain injury and stroke in defined patient populations.

Molecular structure

A mass-spectrometry study identified many peptides in one analyzed fraction. A single molecular formula or peptide sequence would misrepresent this preparation; the study also cannot establish the composition of every lot.

Mechanism under investigation

The mixture has been studied for neurological responses, but the cited trials measure clinical outcomes rather than isolating one confirmed molecular target or mechanism for the preparation.

Research contexts

Published contexts include randomized traumatic-brain-injury trials and systematic reviews of stroke trials. These distinct populations and outcomes should not be combined into a general recovery claim.

Evidence limits

The mixture's composition and patient populations vary. A Cochrane stroke review discusses uncertain evidence and potential harms; findings from TBI trials cannot be transferred to stroke or general cognition claims. Method lot equivalence has not been established.

Primary sources

• Peptide-fraction composition study (PMID 31626174)
• CAPTAIN II TBI trial (PMID 31897941)
• Cochrane stroke review (PMID 37818733)

Overview

Method identifies this product as modified GRF(1–29) without DAC. It is a 29-residue GHRH analogue, distinct from the DAC-bearing albumin bioconjugate examined in the cited CJC-1295 publication.

Molecular structure

The product identity supplied by Method is modified GRF(1–29) without a drug-affinity-complex group. The cited DAC form adds albumin-binding chemistry; its pharmacokinetics and human endocrine results do not describe this non-DAC material.

Mechanism under investigation

GRF analogues are investigated for growth-hormone-releasing hormone receptor activity. The cited DAC research does not establish the response of a no-DAC preparation.

Research contexts

The linked original publication examined GRF(1-29) albumin bioconjugates and receptor activation in rat pituitary research.

Evidence limits

Method has identified the compound class as modified GRF(1–29) without DAC; the exact residue substitutions and lot analysis are not documented here. The cited DAC study cannot establish outcomes for the non-DAC listing.

Primary sources

• Original GRF bioconjugate identity study (PMID 15817669)

Overview

CJC-1295 in the cited studies is a long-acting growth hormone-releasing hormone analogue that binds endogenous albumin. The DAC form should be distinguished from a listing called CJC-1295 No DAC; those names cannot be treated as evidence-equivalent.

Molecular structure

The studied molecule is a modified GHRH analogue with a drug-affinity-complex component associated with albumin binding. Exact supplier-lot identity requires analytical confirmation.

Mechanism under investigation

The cited studies observed sustained changes in growth hormone and IGF-I measures in healthy adults. These endocrine measurements do not establish a general clinical benefit.

Research contexts

Published research includes small, controlled studies of hormone responses in healthy adult volunteers. The record does not transfer those data to CJC-1295 No DAC.

Evidence limits

The studies measured short-term endocrine endpoints in selected volunteers. They do not establish long-term outcomes, broad efficacy, or identity of a catalog sample.

Primary sources

• Healthy-adult endocrine trials (PMID 16352683)
• GH pulsatility study (PMID 17018654)

Overview

DSIP is a nine-residue peptide identified in early rabbit neurophysiology experiments. Two small controlled human studies explored sleep-related measurements. These experiments do not establish a modern clinical sleep indication.

Molecular structure

The originally reported sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. That sequence defines the research peptide, not the identity or purity of a product lot.

Mechanism under investigation

The discovery study recorded delta and spindle EEG responses in rabbits. A specific, clinically validated human receptor mechanism has not been established by the cited sleep studies.

Research contexts

Original research includes rabbit EEG experiments, a six-volunteer crossover study, and a six-participant disturbed-sleep study.

Evidence limits

The human studies were very small and published in 1981. They do not support broad claims for insomnia, mood, pain, or recovery, and they do not establish equivalence to Method inventory.

Primary sources

• Original sequence and rabbit EEG study (PMID 568769)
• Six-volunteer sleep experiment (PMID 6895513)
• Disturbed-sleep experiment (PMID 7028502)

Overview

Epithalon, also spelled Epitalon, is a synthetic tetrapeptide investigated in human cell cultures for telomerase expression and telomere-related measurements. Cell-culture findings cannot establish human longevity outcomes.

Molecular structure

The published tetrapeptide sequence is Ala-Glu-Asp-Gly (AEDG). The name alone does not verify the identity of a Method sample.

Mechanism under investigation

A 2003 experiment reported telomerase activity and telomere changes in cultured human fetal fibroblasts. A later cell-line study investigated hTERT and alternative lengthening pathways; its published correction should be reviewed alongside the paper.

Research contexts

The linked publications study cultured fibroblasts and other human cell lines. These are laboratory systems, not human clinical longevity trials.

Evidence limits

Telomerase expression and telomere length in cultured cells are surrogate endpoints. They do not establish longer lifespan, slower aging, or clinical benefit in people.

Primary sources

• Original fibroblast study (PMID 12937682)
• Cell-line study and correction (PMID 40908429)

Overview

Method identifies its follistatin material as FS-344. FS344 is the 344-residue precursor designation associated with the mature FS315 form after processing. Research using FS288, FS315, or FS344 gene expression must be interpreted by the form and preparation actually tested.

Molecular structure

FS344 denotes a 344-residue follistatin precursor; post-translational processing can yield mature FS315. This differs from the shorter FS288 form. Method's supplied identity is FS-344, but the processing state and lot-specific analytical profile have not been reviewed for this hub.

Mechanism under investigation

Original biochemical work examined follistatin binding to myostatin and inhibition of receptor signaling. Mouse gene-expression experiments tested consequences for muscle endpoints; gene delivery is not equivalent to a supplied protein vial.

Research contexts

The sources include purified-protein signaling assays, transgenic mice, and mouse muscle gene delivery.

Evidence limits

FS344 gene-delivery or expression studies cannot be equated with a supplied protein vial. The listed FS-344 identity does not establish whether the vial contains unprocessed precursor, mature FS315, or a particular mixture; lot analysis is needed for that distinction. Preclinical outcomes are not human-use evidence.

Primary sources

• Myostatin-binding study (PMID 11459935)
• Nonhuman-primate FS344 gene-delivery study (PMID 20368179)
• Human isoform analysis (PMID 15472207)

Overview

Method's FOXO4 product page identifies the material as FOXO4-DRI, a designed D-retro-inverso peptide. The cited original study tested a FOXO4-derived interfering peptide rather than the full FOXO4 transcription-factor protein.

Molecular structure

FOXO4-DRI is a designed peptide construct and is distinct from the parent FOXO4 protein. Method specifies the peptide class on its product page; lot-specific sequence and analytical identity are not independently documented in this research record.

Mechanism under investigation

The original experimental peptide was designed to disturb FOXO4–p53 interaction in senescent-cell models. This proposed mechanism is specific to that research construct.

Research contexts

The linked original paper includes laboratory senescence and mouse models. A later study examines senescent Leydig-cell endpoints in aged mice.

Evidence limits

The sources report cell and mouse-model observations, not human longevity outcomes. Method's listed peptide class matches the research subject, but lot identity and purity require supplier documentation.

Primary sources

• Original FOXO4-derived peptide study (PMID 28340339)
• Aged-mouse Leydig-cell study (PMID 31959736)

Overview

GHK-Cu is a complex of the glycyl-histidyl-lysine tripeptide with copper(II). Original studies examined collagen production in fibroblast cultures and extracellular-matrix accumulation in rat wound chambers. These models do not establish a human treatment outcome.

Molecular structure

The peptide component has three residues: glycine, histidine, and lysine. Copper coordination creates the GHK-Cu complex; the identity of a particular product lot requires analytical confirmation.

Mechanism under investigation

A fibroblast-culture study reported increased collagen synthesis. A rat wound-chamber experiment measured increases in collagen and other matrix components. These observations describe experimental responses, not a validated human clinical mechanism.

Research contexts

Published contexts include fibroblast cultures and implanted wound chambers in rats. They concern matrix biology and experimental wound repair, rather than recommended human use.

Evidence limits

The cited work is in vitro and preclinical. Experimental wound chambers do not measure ordinary human healing outcomes. Formulation and sample identity can also affect interpretation.

Primary sources

• Fibroblast collagen study (PMID 3169264)
• Rat wound-chamber study (PMID 8227353)
• PubChem copper complex identity (CID 71587328)

Overview

A synthetic six-residue growth-hormone secretagogue supplied under an acetate-salt label. Rat pituitary-cell secretagogue experiments and receptor discovery studies. These contexts are research descriptions, not instructions for human use.

Molecular structure

The reported GHRP-6 peptide is His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. Acetate describes a counterion; it does not change the peptide sequence. Verify the listed salt form and lot identity.

Mechanism under investigation

In perifused rat pituitary cells GHRP-6 produced a growth-hormone release response distinguishable from GHRH stimulation.

Research contexts

Rat pituitary-cell secretagogue experiments and receptor discovery studies.

Evidence limits

A cell response and a peptide salt label cannot establish a human performance or body-composition outcome.

Primary sources

• Rat pituitary-cell study (PMID 1674284)
• Secretagogue receptor discovery (PMID 8838145)

Overview

An endogenous tripeptide that participates in cellular redox and metabolic pathways. Experimental glutathione depletion in cultured cells and genetic mouse models of synthesis. These contexts are research descriptions, not instructions for human use.

Molecular structure

Glutathione comprises gamma-glutamyl, cysteinyl, and glycyl units. Its gamma peptide linkage and reduced versus oxidized form matter for analytical identity.

Mechanism under investigation

Mouse disruption of a key glutathione-synthesis enzyme examined the biological requirement for endogenous glutathione.

Research contexts

Experimental glutathione depletion in cultured cells and genetic mouse models of synthesis.

Evidence limits

The requirement for endogenous glutathione does not prove a benefit from any supplied glutathione formulation or route.

Primary sources

• Glutathione-synthesis mouse study (PMC25788)
• Cellular depletion experiment (PMID 9314607)

Overview

A truncated insulin-like growth factor I variant examined in binding-protein and cell models. A primary experiment used cultured rat granulosa cells to compare the analogue with native IGF-I under different IGF-binding-protein conditions. These contexts are research descriptions, not instructions for human use.

Molecular structure

Des(1–3)IGF-I lacks the three N-terminal residues of native IGF-I. Molecular identity and folded protein quality require direct analytical confirmation.

Mechanism under investigation

The truncated analogue bound IGF-binding proteins less strongly while retaining type-I IGF receptor interaction in the cited study.

Research contexts

A primary experiment used cultured rat granulosa cells to compare the analogue with native IGF-I under different IGF-binding-protein conditions.

Evidence limits

A cell-culture potency comparison does not establish human anabolic efficacy or safety, and it does not verify the identity of Method inventory.

Primary sources

• Granulosa-cell binding-protein experiment (PMID 1383276)

Overview

A long-R3 IGF-I analogue studied for reduced IGF-binding-protein affinity. Guinea-pig analogue experiments and in-vitro bovine embryo research. These contexts are research descriptions, not instructions for human use.

Molecular structure

Long R3 IGF-I has an N-terminal extension and an Arg substitution near residue three relative to native IGF-I. Confirm the precise recombinant construct and lot identity.

Mechanism under investigation

Original work compared long R3 IGF-I with native factors, examining organ and circulating IGF-binding-protein endpoints in guinea pigs.

Research contexts

Guinea-pig analogue experiments and in-vitro bovine embryo research.

Evidence limits

Experimental organ and embryo endpoints are not evidence for human body-composition or performance claims.

Primary sources

• Guinea-pig analogue study (PMID 7561636)
• Bovine embryo study (PMID 11181549)

Overview

A synthetic growth-hormone secretagogue examined in animal work and defined human trials. Experimental secretagogue profiling and a randomized phase-2 postoperative-ileus trial in bowel-resection patients. These contexts are research descriptions, not instructions for human use.

Molecular structure

Ipamorelin is a synthetic peptide secretagogue; peptide sequence, salt form, and lot purity require analytical verification.

Mechanism under investigation

Original pharmacology measured growth-hormone secretion and characterized GHRP-like receptor activity.

Research contexts

Experimental secretagogue profiling and a randomized phase-2 postoperative-ileus trial in bowel-resection patients.

Evidence limits

The postoperative trial found no statistically significant difference in its principal or secondary efficacy analyses; endocrine biomarkers do not establish broad benefit.

Primary sources

• Original pharmacology (PMID 9849822)
• Postoperative phase 2 trial (PMID 25331030)

Overview

A ten-residue kisspeptin fragment studied for gonadotropin signaling. Early human reproductive-hormone physiology and direct comparisons with kisspeptin-54 and GnRH. These contexts are research descriptions, not instructions for human use.

Molecular structure

Kisspeptin-10 represents a ten-amino-acid active C-terminal kisspeptin fragment. Check the precise sequence and lot identity against supplier documentation.

Mechanism under investigation

A human experimental study measured luteinizing-hormone secretion and pulse frequency after kisspeptin-10 exposure.

Research contexts

Early human reproductive-hormone physiology and direct comparisons with kisspeptin-54 and GnRH.

Evidence limits

Measured hormone responses in selected participants do not establish fertility treatment suitability or a general human-use protocol.

Primary sources

• Human LH physiology study (PMC3380939)
• Direct peptide comparison (PMID 26089302)

Overview

A Lys-Pro-Val tripeptide derived from the C-terminal region of alpha-MSH. Mouse experimental-colitis models and epithelial/immune-cell studies. These contexts are research descriptions, not instructions for human use.

Molecular structure

The published tripeptide sequence is lysine–proline–valine (KPV). A Method sample requires independent sequence and purity confirmation.

Mechanism under investigation

An original study investigated PepT1-mediated uptake and inflammatory-signaling endpoints in intestinal cells.

Research contexts

Mouse experimental-colitis models and epithelial/immune-cell studies.

Evidence limits

Experimental mouse colitis and cell uptake findings cannot be described as human inflammatory-bowel-disease treatment evidence.

Primary sources

• PepT1 and mouse-colitis study (PMID 18061177)
• Murine model study (PMID 18092346)

Overview

A dual glucagon- and GLP-1-receptor agonist examined in randomized clinical research. A randomized phase-2 trial enrolled Chinese adults meeting defined metabolic-study eligibility criteria under defined eligibility criteria. These contexts are research descriptions, not instructions for human use.

Molecular structure

Mazdutide is a synthetic peptide agonist designed for two receptor systems. A Method lot is not equivalent to the trial drug without analytical and formulation evidence.

Mechanism under investigation

The candidate is designed to activate glucagon and GLP-1 receptors; clinical studies test outcomes rather than proving a simple one-pathway explanation.

Research contexts

A randomized phase-2 trial enrolled Chinese adults meeting defined metabolic-study eligibility criteria under defined eligibility criteria.

Evidence limits

Trial measurements apply to the studied drug, formulation, population, and follow-up. They are not guidance for use of an unverified research product.

Primary sources

• Randomized phase 2 study (PMID 38092790)

Overview

Ibutamoren, an orally active non-peptide growth-hormone secretagogue. A two-year randomized trial examined body-composition and selected clinical endpoints in healthy older adults. These contexts are research descriptions, not instructions for human use.

Molecular structure

MK-677 (ibutamoren) is a small molecule, not an amino-acid-chain peptide. Mesylate and other forms should not be conflated without identity checks.

Mechanism under investigation

The studied compound stimulated growth-hormone and IGF-I responses in older adults.

Research contexts

A two-year randomized trial examined body-composition and selected clinical endpoints in healthy older adults.

Evidence limits

The trial was not powered for functional outcomes, and biomarker or fat-free-mass changes do not establish performance or treatment benefit.

Primary sources

• Older-adult randomized trial (PMID 18981485)

Overview

A mitochondrial 12S-rRNA-derived sixteen-residue peptide described in metabolic models. Mouse high-fat-diet models and laboratory metabolic assays. These contexts are research descriptions, not instructions for human use.

Molecular structure

The original report describes a 16-amino-acid peptide encoded within mitochondrial 12S rRNA. The exact variant and product sequence need verification.

Mechanism under investigation

The original publication investigated metabolic responses and insulin sensitivity in cultured cells and mouse models.

Research contexts

Mouse high-fat-diet models and laboratory metabolic assays.

Evidence limits

Mouse glucose and adiposity endpoints do not establish human human efficacy, longevity, or glucose-control outcomes.

Primary sources

• Original MOTS-c discovery (PMID 25738459)

Overview

Melanotan II, a synthetic cyclic melanocortin analogue studied in receptor and small human studies. A controlled study in men with organic erectile-dysfunction risk factors measured rigidity and reported adverse events. These contexts are research descriptions, not instructions for human use.

Molecular structure

Melanotan II is a cyclic peptide analogue of alpha-MSH. Check the exact cyclic construct, counterion, and lot identity.

Mechanism under investigation

Experimental melanocortin-receptor activation was investigated alongside physiological responses in a ten-person crossover study.

Research contexts

A controlled study in men with organic erectile-dysfunction risk factors measured rigidity and reported adverse events.

Evidence limits

The study enrolled only ten people and recorded nausea, including severe events. It does not establish a safe general-purpose cosmetic or sexual-health use.

Primary sources

• Ten-person crossover experiment (PMID 11018622)

Overview

Nicotinamide adenine dinucleotide, a cellular redox cofactor rather than a peptide. Cellular metabolism research and a short randomized human study of a proprietary oral NAD+ formulation. These contexts are research descriptions, not instructions for human use.

Molecular structure

NAD+ is an oxidized dinucleotide composed of nicotinamide and adenine nucleotide moieties. Salt, stability, and lot identity require verification.

Mechanism under investigation

NAD+ participates in oxidation–reduction reactions and serves as a substrate for certain enzymes. A formulation-specific oral trial measured intracellular NAD-related endpoints.

Research contexts

Cellular metabolism research and a short randomized human study of a proprietary oral NAD+ formulation.

Evidence limits

Results for precursors or a proprietary oral formulation do not establish outcomes for Method NAD+ inventory. Cellular NAD level is not a longevity endpoint.

Primary sources

• Formulation-specific randomized study (PMID 42530810)
• PubChem NAD+ molecular identity

Overview

An endogenous cyclic nonapeptide involved in several physiological signaling systems. In-vitro human uterine-cell receptor pharmacology and comparative ligand-binding experiments. These contexts are research descriptions, not instructions for human use.

Molecular structure

Oxytocin has nine amino-acid residues and an internal disulfide ring. The precise peptide and salt form require lot-specific confirmation.

Mechanism under investigation

An original study characterized labeled oxytocin binding to receptors in human uterine smooth-muscle-cell membranes.

Research contexts

In-vitro human uterine-cell receptor pharmacology and comparative ligand-binding experiments.

Evidence limits

A receptor-binding assay does not establish behavioral, social, or psychiatric effects of a supplied oxytocin product.

Primary sources

• Human uterine-cell receptor assay (PMID 10694212)

Overview

A seven-residue shortened spadin analogue explored as a TREK-1 channel research tool. Transfected-cell electrophysiology and mouse forced-swim research. These contexts are research descriptions, not instructions for human use.

Molecular structure

The original work describes a seven-amino-acid shortened peptide designed from spadin breakdown products. Confirm the exact sequence of the Method lot.

Mechanism under investigation

Investigators screened shortened spadin analogues for TREK-1 channel inhibition and tested selected constructs in mouse behavioral models.

Research contexts

Transfected-cell electrophysiology and mouse forced-swim research.

Evidence limits

A mouse behavioral assay is not evidence for treating depression, and the published derivatives must not be conflated with an unidentified lot.

Primary sources

• Shortened spadin analogue study (PMID 28955242)

Overview

A synthetic Glu-Asp-Arg tripeptide examined in limited cell and hypoxia models. Laboratory cell experiments and an experimental hypobaric-hypoxia model. These contexts are research descriptions, not instructions for human use.

Molecular structure

The reported Pinealon sequence is glutamate–aspartate–arginine (EDR). Confirm identity and peptide quality independently.

Mechanism under investigation

A primary culture study examined cell viability, radical measurements, and proliferation after Pinealon exposure.

Research contexts

Laboratory cell experiments and an experimental hypobaric-hypoxia model.

Evidence limits

Cell viability and animal hypoxia findings do not establish cognitive enhancement, neuroprotection, or human longevity.

Primary sources

• Pinealon cell experiment (PMID 21978084)
• Experimental hypoxia model (PMID 18546825)

Overview

A designed p53-derived peptide construct studied for membrane responses in cancer-cell models. Human tumor-cell-line experiments and peptide NMR structure research. These contexts are research descriptions, not instructions for human use.

Molecular structure

Published PNC-27 joins a p53-derived segment to a membrane-associated leader. Method describes its product as a p53-derived chimeric peptide with a membrane-penetrating or membrane-residency segment. Its public listing names the construct class but does not provide a lot-specific sequence report.

Mechanism under investigation

A primary structural study examined the peptide conformation and its proposed interaction with HDM2-associated cancer-cell membranes.

Research contexts

Human tumor-cell-line experiments and peptide NMR structure research.

Evidence limits

The published cell-line results concern the complete chimeric construct, including its leader. Method's listed construct class is consistent with that design, but an exact sequence or lot certificate is needed to establish molecular equivalence. Cell-line results are not treatment evidence.

Primary sources

• PNC-27 NMR and cancer-cell study (PMID 14967026)
• Original p53-derived constructs (PMC60072)

Overview

Bremelanotide, a melanocortin-receptor peptide analogue tested in randomized human trials. Two randomized trials enrolled a defined population of premenopausal women with hypoactive sexual-desire disorder. These contexts are research descriptions, not instructions for human use.

Molecular structure

PT-141 is the development name associated with bremelanotide, a synthetic cyclic peptide. The studied formulation and a research lot are distinct.

Mechanism under investigation

The trial drug acts through melanocortin signaling; the source trials measured patient-reported desire and distress endpoints.

Research contexts

Two randomized trials enrolled a defined population of premenopausal women with hypoactive sexual-desire disorder.

Evidence limits

The trial outcomes apply to the approved drug formulation and studied population, not automatically to Method inventory or other groups.

Primary sources

• RECONNECT phase 3 trials (PMID 31599840)

Overview

Retatrutide, also called LY3437943, was investigated in randomized phase 2 studies involving adults meeting defined metabolic or diabetes-study eligibility criteria. The published trial findings concern those defined study populations and formulations.

Molecular structure

Retatrutide is an engineered peptide agonist. Exact sequence and product-form identity should be confirmed from authoritative chemistry records and lot-specific analytics before listing a sequence for Method inventory.

Mechanism under investigation

The phase 2 publications identify retatrutide as an agonist of GIP, GLP-1, and glucagon receptors. Receptor activity is a studied pharmacologic property; trial outcomes cannot be extrapolated to an unverified research product.

Research contexts

Published human research includes a randomized placebo-controlled metabolic trial and a randomized diabetes trial. These are clinical research settings, not guidance for use of Method inventory.

Evidence limits

The cited reports are phase 2 studies with defined eligibility criteria and follow-up. They do not establish long-term outcomes for all populations or equivalence between a trial drug and a catalog product.

Primary sources

• Phase 2 metabolic trial (PMID 37366315)
• Type 2 diabetes phase 2 trial (PMID 37385280)

Overview

A nonsteroidal antiandrogen investigated in hair-follicle and scalp-graft models; it is not a peptide. Ex-vivo human scalp tissue transplanted into a mouse model. These contexts are research descriptions, not instructions for human use.

Molecular structure

RU58841 is an organic small molecule, not an amino-acid-chain peptide. Molecular identity and lot impurities require analytical confirmation.

Mechanism under investigation

An original study evaluated local androgen antagonism in human balding scalp grafts maintained on testosterone-conditioned nude mice.

Research contexts

Ex-vivo human scalp tissue transplanted into a mouse model.

Evidence limits

Human-derived grafts on mice are not a human clinical trial; the cited experiment does not establish a safe or effective consumer hair treatment.

Primary sources

• Human scalp-graft mouse study (PMID 9415227)

Overview

A synthetic seven-residue peptide studied in limited neurobiology and clinical research. A Russian-language clinical report investigated selected patients with generalized anxiety and neurasthenia. These contexts are research descriptions, not instructions for human use.

Molecular structure

The reported Selank sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro. Lot sequence and chemical form require verification.

Mechanism under investigation

Published work examines peptide-associated neurochemical and behavioral measurements; it has not established one validated human molecular receptor target.

Research contexts

A Russian-language clinical report investigated selected patients with generalized anxiety and neurasthenia.

Evidence limits

The limited report and its population cannot support broad claims for anxiety, cognition, or safe use of a Method sample.

Primary sources

• Clinical report (PMID 18454096)

Overview

A synthetic ACTH-derived peptide explored in laboratory and small neurological studies. Laboratory cerebral-ischemia research and a report involving 30 patients with acute hemispheric ischemic stroke. These contexts are research descriptions, not instructions for human use.

Molecular structure

Semax combines an ACTH-derived N-terminal segment and Pro-Gly-Pro extension. Verify the exact studied sequence and Method lot.

Mechanism under investigation

Original experimental work examined neurotrophin and receptor-gene transcription after cerebral-ischemia models.

Research contexts

Laboratory cerebral-ischemia research and a report involving 30 patients with acute hemispheric ischemic stroke.

Evidence limits

The small clinical literature does not establish broad cognitive enhancement or a treatment recommendation for a research product.

Primary sources

• Neurotrophin transcription study (PMID 19633950)
• Thirty-patient clinical report (PMID 11517472)

Overview

A synthetic estrogen-related-receptor agonist studied in cells and mice, not a peptide. Cell-based receptor assays, mouse exercise-capacity models, and later mouse metabolic-syndrome research. These contexts are research descriptions, not instructions for human use.

Molecular structure

SLU-PP-332 is an organic small molecule rather than an amino-acid peptide. Chemical identity and lot verification matter.

Mechanism under investigation

The original publication identified an ERR pan agonist and tested an ERRα-dependent gene-expression response.

Research contexts

Cell-based receptor assays, mouse exercise-capacity models, and later mouse metabolic-syndrome research.

Evidence limits

Mouse exercise and metabolic endpoints do not establish a human exercise effect, metabolic outcome, or safety profile.

Primary sources

• ERR agonist discovery (PMID 36988910)
• Mouse metabolic study (PMID 37739806)

Overview

Acetyl octapeptide-3, a synthetic cosmetic peptide present in multi-ingredient formulations. A human microneedle-patch study measured skin endpoints for a combined formulation. These contexts are research descriptions, not instructions for human use.

Molecular structure

SNAP-8 is associated with an acetylated eight-residue peptide. Verify its exact sequence and capping groups against the Method lot.

Mechanism under investigation

The accessible clinical study tested a patch containing acetyl octapeptide-3 plus several other active ingredients; it cannot isolate this peptide’s mechanism.

Research contexts

A human microneedle-patch study measured skin endpoints for a combined formulation.

Evidence limits

Do not attribute wrinkle or skin changes in the multi-ingredient patch to SNAP-8 alone. A standalone clinical benefit remains unsupported by this source.

Primary sources

• Multi-ingredient patch study (PMID 31134751)

Overview

Elamipretide, an aromatic-cationic tetrapeptide investigated in mitochondrial and human trials. A randomized phase-3 trial evaluated adults with genetically confirmed primary mitochondrial myopathy. These contexts are research descriptions, not instructions for human use.

Molecular structure

The studied SS-31/elamipretide sequence includes D-Arg and a dimethyl-tyrosine residue. Those nonstandard features require direct lot-identity confirmation.

Mechanism under investigation

Experimental work associates the peptide with inner-mitochondrial-membrane cardiolipin. Clinical studies tested functional rather than merely biochemical endpoints.

Research contexts

A randomized phase-3 trial evaluated adults with genetically confirmed primary mitochondrial myopathy.

Evidence limits

The phase-3 study did not show significant improvement on its primary endpoints in the studied diverse population. Other conditions and formulations require separate evidence.

Primary sources

• MMPOWER-3 phase 3 trial (PMID 37268435)
• Early randomized trial (PMID 29500292)

Overview

A selective phosphodiesterase-5 inhibitor studied in human trials; it is not a peptide. Enzyme/medicinal chemistry and randomized human erectile-function studies. These contexts are research descriptions, not instructions for human use.

Molecular structure

Tadalafil is a defined organic small molecule. A product named tadalafil needs chemical identity and impurity verification, not a peptide sequence.

Mechanism under investigation

Original medicinal-chemistry research identified a stereochemically defined PDE5 inhibitor; clinical trials measured specified outcomes in defined patient groups.

Research contexts

Enzyme/medicinal chemistry and randomized human erectile-function studies.

Evidence limits

An established drug’s clinical trials do not verify Method inventory or support advice on human use in this research hub.

Primary sources

• PDE5 inhibitor discovery (PMID 14521415)
• Human controlled trial (PMID 15708052)

Overview

Method identifies its TB-500 material as Ac-LKKTETQ, the N-terminally acetylated seven-residue fragment corresponding to thymosin beta-4 residues 17–23. Published analytical work identified this structure in a TB-500 sample. The fragment is distinct from full-length thymosin beta-4.

Molecular structure

Ac-LKKTETQ contains seven amino acids and an N-terminal acetyl group. It corresponds to residues 17–23 of the 43-residue thymosin beta-4 protein; findings for the complete protein must not be assigned to the fragment by name alone.

Mechanism under investigation

A 2024 study measured TB-500 and metabolites and compared responses in fibroblast assays. It reported a signal for a metabolite rather than establishing a clinically validated mechanism for the parent fragment.

Research contexts

The cited work includes chemical identification, equine analytical detection, rat metabolism, and in-vitro fibroblast assays. Full-length thymosin beta-4 wound studies should not be assigned to TB-500 without proof that the studied molecule matches.

Evidence limits

This identity is supplied by Method; a lot-specific sequence and analytical report have not been reviewed for the hub. Analytical and cell findings do not establish human efficacy or safety. Full-length thymosin beta-4 studies are separate evidence.

Primary sources

• Fragment identification (PMID 22962027)
• TB-500 metabolite and cell study (PMID 38382158)
• Full-length thymosin beta-4 characterization (PMID 7054160)

Overview

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone. Randomized studies investigated visceral adipose tissue in adults with HIV-associated abdominal fat accumulation. Those findings apply to their study populations and tested drug formulation.

Molecular structure

Tesamorelin is a modified peptide analogue of human growth hormone-releasing hormone. An exact sequence claim for Method stock requires confirmation of the supplied material and its form.

Mechanism under investigation

Tesamorelin acts through growth hormone-releasing hormone signaling. The cited trials measured visceral adipose tissue and endocrine or metabolic markers; these endpoints should be distinguished from broad body-composition claims.

Research contexts

Published research includes placebo-controlled clinical trials in adults with HIV-associated abdominal fat accumulation, including a smaller liver-fat investigation.

Evidence limits

The cited trial populations are specific. Results do not establish effects in unrelated populations or equivalence between an approved formulation and an unverified catalog lot. The smaller liver-fat trial noted the need for further study of clinical importance and long-term effects.

Primary sources

• Randomized visceral-fat trial (PMID 18057338)
• HIV abdominal-fat trial (PMID 20101189)
• Liver-fat trial (PMID 25038357)

Overview

A 28-residue thymosin peptide examined in immune-cell and defined clinical research. In-vitro human CD14+ monocyte experiments and mouse antifungal-immunity models. These contexts are research descriptions, not instructions for human use.

Molecular structure

Thymosin alpha-1 is a twenty-eight-amino-acid peptide. Verify sequence, acetylation, and analytical identity of the supplied lot.

Mechanism under investigation

An original study examined differentiation and functional maturation of human monocyte-derived dendritic cells.

Research contexts

In-vitro human CD14+ monocyte experiments and mouse antifungal-immunity models.

Evidence limits

Immune-cell maturation and mouse infection endpoints do not establish a broad immune-boosting benefit or human treatment use of Method inventory.

Primary sources

• Human dendritic-cell study (PMID 17532057)
• Mouse antifungal model (PMID 14982877)

Overview

Vasoactive intestinal peptide, a 28-residue neuropeptide studied in receptor and cell models. Human colon-carcinoma and lymphoblast cell-line receptor assays. These contexts are research descriptions, not instructions for human use.

Molecular structure

VIP is a twenty-eight-residue peptide; related fragments such as VIP4–28 are distinct molecules. Confirm full-length sequence and lot identity.

Mechanism under investigation

A primary study compared full-length VIP and fragments for VPAC receptor binding and cAMP signaling in defined cell lines.

Research contexts

Human colon-carcinoma and lymphoblast cell-line receptor assays.

Evidence limits

Cell-line receptor responses cannot establish clinical outcomes for inflammation, cognition, or vascular conditions.

Primary sources

• VPAC receptor cell study (PMID 12750439)